| Dr David S Harris, MD | |
|
6811 Palisades Park Ct Ste 1, Fort Myers, FL 33912 | |
| (239) 533-5177 | |
| (239) 322-5610 |
| Full Name | Dr David S Harris |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 39 Years |
| Location | 6811 Palisades Park Ct Ste 1, Fort Myers, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215913975 | NPI | - | NPPES |
| P01193238 | Other | FL | RAILROAD MCR |
| 4694542 | Other | FL | CIGNA |
| P986298 | Other | FL | FREEDOM HEALTH |
| 1193104 | Other | FL | WELLCARE |
| 003545700 | Medicaid | FL | |
| 1488H | Other | FL | BCBS OF FL |
| 5972493 | Other | FL | AETNA |
| 10P566 | Other | FL | HEALTHY KIDS |
| 341114 | Other | FL | AVMED |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | ME106641 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Trilogy Home Healthcare | Estero, FL | Home health agency |
| Gulf Coast Medical Center Lee Health | Fort myers, FL | Hospital |
| Lee Memorial Hospital | Fort myers, FL | Hospital |
| Cape Coral Hospital | Cape coral, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Urology Institute Llc | 2163653585 | 114 |
News Archive
Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.
People with a gene variation of FGF21 have a predisposition to less body fat than others, new research conducted at the University of Copenhagen, among others, shows.
› Verified 9 days ago
| Entity Name | Advanced Urology Institute Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023447935 PECOS PAC ID: 2163653585 Enrollment ID: O20140328000990 |
News Archive
Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.
People with a gene variation of FGF21 have a predisposition to less body fat than others, new research conducted at the University of Copenhagen, among others, shows.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David S Harris, MD 12109 County Road 103, Oxford, FL 34484-2951 Ph: (352) 205-8981 | Dr David S Harris, MD 6811 Palisades Park Ct Ste 1, Fort Myers, FL 33912 Ph: (239) 533-5177 |
News Archive
Studies indicate that the majority of people with mood and anxiety disorders who receive the most commonly prescribed class of antidepressant medications, Selective Serotonin Reuptake Inhibitors or SSRI's, are not helped by these medications. SSRIs are designed to increase serotonin, a neurotransmitter in the brain that is key to maintenance of mood.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
W. L. Gore & Associates (Gore) today provided an update on the Gore REDUCE Clinical Study, a prospective, randomized, multi-center, multi-national trial designed to demonstrate safety and effectiveness of the GORE HELEX Septal Occluder for Patent Foramen Ovale (PFO) closure in patients with history of cryptogenic stroke or imaging-confirmed Transient Ischemic Attack (TIA). The unique study, which includes up to fifty investigational sites in the U.S., Denmark, Finland, Norway and Sweden, is on track to meet its estimated completion in 2015.
People with a gene variation of FGF21 have a predisposition to less body fat than others, new research conducted at the University of Copenhagen, among others, shows.
› Verified 9 days ago
Dr. Kyle Matthew Waisanen, MD Urology Medicare: Medicare Enrolled Practice Location: 12651 Whitehall Dr, Fort Myers, FL 33907 Phone: 239-424-2030 Fax: 239-343-4117 | |
Barry F Blitz, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 7451 Gladiolus Dr, Fort Myers, FL 33908 Phone: 239-689-8800 Fax: 239-939-7774 | |
Dr. Joseph Clair Klink, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 8931 Colonial Center Dr Ste 401, Fort Myers, FL 33905 Phone: 239-396-8930 Fax: 239-396-8932 | |
Scott Raymond Caesar, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 8931 Colonial Center Dr, Suite 100, Fort Myers, FL 33905 Phone: 239-458-1196 Fax: 239-458-1345 | |
Brett Michael Giblin, Urology Medicare: Medicare Enrolled Practice Location: 12651 Whitehall Dr, Fort Myers, FL 33907 Phone: 239-424-2030 Fax: 239-343-4117 | |
Bert F Van Beever, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 7451 Gladiolus Dr, Fort Myers, FL 33908 Phone: 239-689-8800 Fax: 239-939-7774 |